|Brand name(s), other common name(s)||Venclexta®|
|Drug type||BCL-2 inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Venetoclax is FDA approved
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Side effects needing medical attention
Neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Serious adverse reactions were pneumonia, febrile neutropenia, pyrexia (fever), autoimmune hemolytic anemia, anemia, and tumor lysis syndrome (TLS).
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.